1-3 of 3
Jamie Brower
Close
Sort by
Journal Articles

Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel

Nausheen Ahmed, William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Jamie Brower, Gunjan L Shah, Andy I. Chen, Olalekan O. Oluwole, Stephen J. Schuster, Michael R Bishop, Joseph P. McGuirk, Peter A. Riedell
Journal: Blood Advances
Blood Adv bloodadvances.2023012549.
https://doi.org/10.1182/bloodadvances.2023012549
Published: 2024
Includes: Supplemental data
Journal Articles

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Clinical Trials & Observations
Michael Scordo, Jessica R. Flynn, Mithat Gonen, Sean M. Devlin, Allison Parascondola, Ana Alarcon Tomas, Roni Shouval, Jamie Brower, David L. Porter, Stephen J. Schuster, Veronika Bachanova, Joseph Maakaron, Richard T. Maziarz, Andy I. Chen, Loretta J. Nastoupil, Joseph P. McGuirk, Olalekan O. Oluwole, Andrew Ip, Lori A. Leslie, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5579–5585.
https://doi.org/10.1182/bloodadvances.2023010302
Published: 2023
Includes: Supplemental data
Journal Articles

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Clinical Trials & Observations
Kitsada Wudhikarn, Ana Alarcon Tomas, Jessica R. Flynn, Sean M. Devlin, Jamie Brower, Veronika Bachanova, Loretta J. Nastoupil, Joseph P. McGuirk, Richard T. Maziarz, Olalekan O. Oluwole, Stephen J. Schuster, David L. Porter, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3192–3198.
https://doi.org/10.1182/bloodadvances.2022008294
Published: 2023
Includes: Supplemental data